Cipla Shares Surge 4% as Citi Forecasts Major Growth Catalysts

Cipla shares witnessed a significant rally on Monday, climbing 4% to hit a high of Rs 1,409 on the BSE. This optimism follows a strategic move by international brokerage Citi, which has placed the pharmaceutical giant on a "90-day Positive Catalyst Watch."

US Market Triggers and Product Pipeline

The primary driver behind Citi’s bullish stance is a series of upcoming regulatory and product milestones in the United States. The brokerage maintained a ‘Buy’ rating with a target price of Rs 1,700, suggesting a potential upside of over 25% from current levels.

Key US-centric triggers include the anticipated approval of gFlovent from Cipla’s Goa facility, which is expected to significantly bolster growth in the American market. Additionally, the upcoming launch of gVentolin is viewed as a vital driver. Citi also highlighted Cipla's strong competitive position, noting that its Nintedanib has already captured nearly 50% of the US market share. This momentum is expected to lead to a revenue rebound in the US segment following a recent period of weakness.

Domestic Resilience and Regulatory Outlook

While the US market offers high-growth potential, Cipla’s domestic operations remain a bedrock of stability. The India business, which contributes approximately two-thirds of the company's EBITDA, is performing robustly, supported by a recovery in its respiratory portfolio.

Investors are also eyeing regulatory developments at the Indore plant. A re-inspection is due at any time, and Citi suggests that a favorable outcome and subsequent USFDA clearance would serve as a powerful additional catalyst for the stock. Furthermore, easing geopolitical tensions are expected to stabilize raw material costs, potentially aiding margin recovery.

Valuation and Financial Context

Despite a challenging Q4—where consolidated net profit fell 55% YoY to Rs 555 crore and revenue slipped 3% to Rs 6,541 crore—Citi believes the company's earnings have bottomed out following the impact of gRevlimid.

From a valuation perspective, Cipla appears attractive compared to its domestic peers. The brokerage noted that Cipla’s India business is valued at 7.8 times FY26 sales, which is more reasonable than Mankind Pharma, which trades at 8.5 times. Currently, the stock trades at 25x FY27E earnings and 21x FY28E earnings, presenting what Citi describes as a favorable risk-reward profile.

Key Takeaways

  • Target Upside: Citi maintains a 'Buy' rating with a target price of Rs 1,700, implying a 25.55% upside.
  • US Growth Drivers: Upcoming catalysts include the expected launch of gVentolin and the approval of gFlovent to drive US revenue.
  • Attractive Valuation: Cipla offers a more reasonable valuation for its India business (7.8x FY26 sales) compared to peers like Mankind (8.5x).